Palvella Therapeutics, Inc.
PVLA
Positions held
Your positionsPVLA isn't in your positions.
Add it to see shares, cost, and P&L here.
Bull / bear case
Site-generated summary from fundamentals, news, and score — not investment advice. As of 2026-10-08.
- Palvella Therapeutics operates in the biotechnology sector, which is known for its potential to innovate and address unmet medical needs, attracting significant investor interest.
- The company has a market capitalization of approximately $1.84 billion, indicating a substantial valuation in the biotech space.
- Palvella's target mean price is $230.53, suggesting a significant upside potential from its current trading levels.
- The company's financials show a concerning trend with a net income of -21.87 million in Q2 2026, reflecting ongoing losses.
- Palvella has reported zero revenue for multiple quarters, including the last four quarters, which raises questions about its operational viability.
- The stock has a 'Strong Sell' signal with a score of -16.00, indicating negative market sentiment and technical indicators pointing towards further declines.
Fundamentals
| Market cap | $1.89B | Enterprise value | $1.66B | Trailing P/E | — | Forward P/E | -17.52 |
| PEG | — | Price / book | 8.72 | Beta | — | Dividend yield | 0.00% |
| Revenue growth | — | Earnings growth | — | Gross margin | 0.0% | Operating margin | 0.0% |
| Profit margin | 0.0% | ROE | -46.6% | ROA | -22.1% | Debt / equity | 0.10 |
| Current ratio | 21.18 | Free cash flow | -$25.45M | Analyst recommendation | none | Mean target | $230.53 |
| 52w high | $161.38 | 52w low | $65.93 |
Quarterly
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | |
|---|---|---|---|---|---|---|
| Revenue | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | — |
| Op margin | — | — | — | — | — | — |
| Net income | -$21.9M | -$15.8M | -$12.7M | -$11.3M | -$9.5M | — |
| Gross margin | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — |
| Operating income | -$21.4M | -$14.9M | -$11.3M | -$10.2M | -$9.3M | — |
Yearly (6y)
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Revenue | $0.0M | $0.0M | $0.0M | $0.0M |
| Op margin | — | — | — | — |
| Net income | -$41.7M | -$17.4M | $18.7M | -$27.6M |
| Gross margin | — | — | — | — |
| Gross profit | — | — | — | — |
| Operating income | -$38.6M | -$14.1M | -$11.9M | -$18.0M |
No flags
• No distress or material-risk keywords in recent headlines (keyword scan only — not a guarantee).
News
2026-09-28 · Palvella Therapeutics Wins Additional US FDA Grant Funding for Rare Skin Disease Drug
2026-09-02 · Palvella Therapeutics to Participate in Upcoming Healthcare Investor Conferences
2026-08-31 · Palvella Therapeutics Completes Rolling Submission of NDA for QTORIN Rapamycin
2026-08-26 · Ligand Pharmaceuticals Highlights XOMA-Fueled Royalty Growth, $700M in Deployable Capital
2026-08-16 · Palvella Therapeutics Eyes 2027 QTORIN Approval as Rare-Disease Pipeline Expands
2026-08-11 · Palvella (PVLA) Q2 2026 Earnings Call Transcript
2026-08-08 · Is Palvella Therapeutics (PVLA) Fully Valued Ahead Of QTORIN Approval?
2026-08-05 · Palvella Therapeutics to Participate in the Canaccord Genuity 46th Annual Growth Conference
2026-08-04 · Palvella Therapeutics, Inc. Q2 2026 Earnings Call Summary
Price (daily)
Full chart · RSI · MACD · patterns